Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment... | May 31, 2023

Related Keywords

Horsham ,Saskatchewan ,Canada ,Pennsylvania ,United States ,Milan ,Lombardia ,Italy ,Japan ,Spring House ,Canadian ,Zismand Comorbidities ,Laura Coates ,Terence Rooney ,Craig Stoltz ,Scandj Rheumatol ,National Library Of Medicine ,Stanford Health Assessment Questionnaire ,Canadian Agency For Drugs Technologies In Health ,Janssen Scientific Affairs ,Janssen Pharmaceutical Companies ,Arthritis Foundation ,Devices Agency ,Exchange Commission ,Johnson ,Janssen Pharmaceutical Companies Of Johnson ,Japan Pharmaceuticals ,European Medicines Agency ,Companies Of Johnson ,None Of The Janssen Pharmaceutical Companies ,Drug Administration ,Janssen Biotech Inc ,Health Assessment Questionnaire ,Janssen Research Development ,University Of Oxford ,Senior Clinical Research ,National Psoriasis Foundation ,European Congress ,Psoriasis Area ,Severity Index ,Leeds Enthesitis Index ,Senior Clinical Research Fellow ,Vice President ,Maternal Fetal Immunology Disease Area Leader ,Janssen Research ,Psoriatic Arthritis ,Allergic Reactions Stop ,Prescribing Information ,Medication Guidefor ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Inadequate Response ,Receiving Guselkumab ,Between Patient ,Physician Global Assessment Over Time ,Accessed May ,Rheum Dis ,Swollen Joint Counts ,Modified Rodnan Skin Score ,Early Diffuse Cutaneous Systemic Sclerosis ,Prospective Registry ,Early Systemic Sclerosis ,National Library ,Accessed April ,Active Psoriatic Arthritis ,Anti Tumor Necrosis Factor Alpha ,New Phase ,Data Show First In Class ,Achieved Robust Joint Symptom Improvement ,Complete Skin Clearance ,Tumor Necrosis Factor Inhibition ,Ann Rheum Dis ,Provides Sustained Improvement ,Patients Who Were Biologic Na ,Guselkumab Through ,Patients With Active Psoriatic Arthritis ,Previously Received ,Inhibitor Treatment ,Placebo Controlled Phase ,Term Efficacy ,Monoclonal Antibody Specific ,Through Two Years ,Results From ,Placebo Controlled Study Conducted ,Biologic Naive Patients With Active Psoriatic ,Arthritis Rheumatol ,Study Evaluating ,Guselkumab Administered Subcutaneously ,Alpha Agent ,Participants With Active Psoriatic ,Sausage Finger Swelling You Should Know ,About Psoriatic ,Immune Based Ther Vaccines ,Last Updated July ,Medical Devices ,Tremfya Report ,Canadian Agency ,Inflammatory Mononuclear Phagocyte ,T Cell Profiles ,Psoriatic Skin ,Specific Monoclonal Antibody ,Myeloid Cells ,Potently Neutralises ,Johnson Stock Exchange ,News ,Information ,Press Release ,Spring ,Bay ,023 ,The ,Janssen ,Harmaceutical ,Companies ,F ,Oday ,Nnounced ,Few ,Data ,Rom ,Hase ,Tb ,Cosmos ,Linical ,Trial ,Showing ,Hat Jnj Us4781601046 ,